Aktienanalyse zu Precigen Inc (PGEN)PGENPrecigen Inc

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Precigen Inc appears to be a good buy right now, with a current price of $6.95 and a significant gross margin of 94.90% reported in Q2 2026. The company has shown impressive revenue growth, achieving $55 million in Q2 2026, which is a 145% increase from the previous quarter. This growth is driven by the successful launch of its PAPZIMEOS treatment, which has received FDA orphan drug status, enhancing its market competitiveness. However, a potential risk is the insider selling activity, where the CFO sold 200,000 shares, reducing his holdings by 36%, which may raise concerns about insider confidence.